Rethink Impact invests in Evvy
Funding Provisional 90% confidence first seen
Rethink Impact participated as a new investor in Evvy’s $40 million Series B funding round. The round was reported as led by Catalio Capital Management, with other new investors including the U.S. Fertility Innovation Fund, Muse Capital, and Alumni Ventures. The investment matters because Evvy plans to use the proceeds to validate AI-enabled diagnostic and care models, starting with fertility-focused care, to improve precision women’s health outcomes.
The deal
Evvy $40M Series B · announced 15 Sep 2026
Investors Alumni Ventures Catalio Capital Management
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Rethink Impact joined Evvy as a new investor in Evvy’s reported $40 million Series B round, which SiliconANGLE said will fund expansion of the company’s precision diagnostics and care platform. Evvy said it will use the capital to validate new AI-enabled diagnostic and care models, starting with fertility-focused care.
- Why it matters
- This event signals additional capital flowing into AI-enabled women’s health, specifically into diagnostic and care workflows rather than a general-purpose AI platform. For decision-makers in healthcare, diagnostics, and digital health, the funding supports Evvy’s effort to generate validation for fertility-focused models, which could affect partnership, competitive, and care-delivery decisions if the company’s reported clinical performance translates at scale.
- Evidence
- The provided coverage is a single report from SiliconANGLE stating that Evvy raised a $40 million Series B, is scaling its precision diagnostics and care platform, and plans to validate AI-enabled diagnostic and care models beginning with fertility-focused care. The same report cites company-stated outcomes, including diagnosing more than 90% of symptomatic patients and reducing recurrence of some conditions by 50%; no independent confirmation is included in the provided coverage.
- What remains uncertain
- The coverage does not independently verify Evvy’s reported clinical outcomes, the exact role or check size of Rethink Impact in the round, or how quickly the new diagnostic and care models will be validated and commercialized. It is also unclear from the provided report how broadly Evvy’s results generalize across populations, clinical settings, or payer/provider adoption scenarios.
- Monitor next
- Watch for published clinical validation data or announced provider, fertility-clinic, or payer partnerships tied to Evvy’s new AI-enabled fertility care models.
Analytical support, not advice — assumptions and open questions stated above.